It has been found that the activity of AMPK is inhibited in DN, and AMPK activator can alleviate the proteinuria, mesangial expansion, and increased TGF-β levels [15], which are considered to be signs of clinical and pathological changes in DN [43]. The gene discussed is PRKAA2; the disease is liver dysplastic nodule.